Best Neurology Companies in Toronto, Canada
The 42 best Neurology companies in Toronto, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ProMIS Neurosciences.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Toronto
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ProMIS Neurosciences Antibody therapeutics and diagnostics for neurodegenerative diseases 37Funding top 10%Patents top 38%Moat top 38%Talent top 38% All 9 signals ▾Fundingtop 10% Patentstop 38% Moattop 38% Talenttop 38% Newstop 42% Innovationtop 47% Globalbottom 48% Techbottom 34% Marketbottom 24% Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $247M | 7 mo ago | 7 | Neil Cashman Co-Founder | BootstrapApache HTTP ServerjQuery+10 | Top 10M | 78 patents Therapeutic antibodies targeting misfolded neurodegeneration proteins (TDP-43, α‑synuclein, Aβ, SOD1). | — |
| 2 | Cybin Provider of psychedelic therapeutics for psychiatric disorders 55Funding top 15%Tech top 42%Talent top 45%Moat top 48% All 6 signals ▾Fundingtop 15% Techtop 42% Talenttop 45% Moattop 48% Marketbottom 47% Globalbottom 37% Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 55/100 | $230M | 14 mo ago | 50 | Aaron Bartlone COO | BugHerdQ4MediaElement.js+17 | Top 5M | — | — |
| 3 | Transition Therapeutics Small molecule therapeutics for CNS and metabolic diseases. | $113M | 146 mo ago | 18 | — | — | — | 15 patents Peptide and vitamin B12‑based therapeutics for cardiovascular, metabolic, and antiviral diseases | — |
| 4 | Reunion Neuroscience Developer of therapeutics for mental health conditions | $103M | 31 mo ago | 18 | — | WordPressMySQLPHP+17 | Top 50M | 12 patents Novel tryptamine prodrugs and benzyltryptamine derivatives for CNS therapeutics. | — |
| 5 | BIONIK Provider of assistive and rehabilitation hardware and software solutions | $40M | 111 mo ago | 12 | Michal Prywata Co-Founder | — | — | — | — |
| 6 | Cynapsus Therapeutics Developer of treatment for CNS disorders | $25M | 136 mo ago | 30 | — | — | — | 47 patents Sublingual apomorphine delivery systems for rapid Parkinson's symptom relief | — |
| 7 | Grey Matter Neurosciences Developer of medical devices for neurological disease treatment | $14M | 19 mo ago | — | Jeffrey Coull Founder & CEO | WordPressMySQLPHP+17 | Top 50M | — | — |
| 8 | NoNO Developing pharmaceuticals for the treatment of common health disorders, including stroke, traumatic brain… | $10M | 159 mo ago | 43 | Michael Tymianski President and CEO | — | — | 370 patents Peptide-based neuroprotective and ischemia therapies using modified peptide salts | — |
| 9 | Psyence Developer of psychedelic therapeutics for mental health disorders 45News top 26%Growth top 36%Funding top 40%Global top 41% All 7 signals ▾Newstop 26% Growthtop 36% Fundingtop 40% Globaltop 41% Talenttop 49% Marketbottom 43% Techbottom 36% News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $9M | 14 mo ago | — | Alan Friedman Co-Founder | WordPressMySQLPHP+22 | Top 10M | — | — |
| 10 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 18 mo ago | 9 | Yulong Sun Co-Founder | — | — | 5 patents Monoclonal antibodies specific for conformational epitopes of lambda immunoglobulin light chains | — |
| 11 | Winterlight Labs AI-powered speech analysis technology to detect cognitive impairments | $6M | 81 mo ago | 48 | Maria Yancheva Co-Founder And Chief Technology Officer | — | — | 7 patents AI-driven speech analysis for diagnosing cognitive and neurological disorders | — |
| 12 | DAMONA Pharmaceuticals Developer of therapeutics for the treatment of cognitive dysfunctions | $6M | 47 mo ago | 6 | Etienne Sibille Founder | — | — | — | — |
| 13 | ClaroNav Developer of medical 3D visualization and surgical navigation solutions | $2M | 79 mo ago | 40 | Doron Dekel Co-Founder & Co-CEO | Framer SitesReactLenis+8 | Top 50M | 35 patents Dental navigation and robotic tool calibration for precise oral surgery procedures. | — |
| 14 | KalGene Pharmaceuticals Developing therapeutics and companion diagnostics for Cancer and Alzheimer's. | $2M | 55 mo ago | 2 | — | — | — | — | — |
| 15 | Steadiwear Designer & manufacturer of healthcare gloves 29Growth top 35%Moat top 38%Tech top 42%Funding bottom 49% All 10 signals ▾Growthtop 35% Moattop 38% Techtop 42% Fundingbottom 49% Talentbottom 49% Productbottom 47% Innovationbottom 40% Globalbottom 39% Patentsbottom 37% Marketbottom 17% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $1M | 11 mo ago | 6 | Mark Elias Co-Founder & CEO | ShopifyShop PayPayPal+32 | Top 5M | 8 patents Wearable tremor‑damping devices for involuntary hand motion control | — |
| 16 | Quantum Biopharma Developer of therapies for neurodegenerative and neuropsychiatric diseases | $500K | 9 mo ago | — | Anthony Durkacz Co-Founder | DudaYouTubeReact+16 | Top 10M | — | 1 launch |
| 17 | Neural Therapeutics Developer of ethnobotanical drug for neurological disorder | $495K | 17 mo ago | 2 | Ian Campbell Chief Executive Officer | — | — | — | — |
| 18 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 37 mo ago | — | Paul Slyke Co-Founder & CSO | — | — | — | — |
Top 12 Neurology companies in Toronto
#1
Public · Toronto, Ontario · founded 2004 · 7 employees$247.3Mraised▾
ProMIS Neurosciences discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company utilizes its computational discovery platform, ProMIS, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. It owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
- Jan 2026Post IPO$175M
- Jul 2025Post IPO$9.2M
- Sep 2023Post IPO$14.9M
- Oct 2022Post IPO$7.5M
#2
Public · Toronto, Ontario · founded 2002 · 50 employees$229.7Mraised▾
Provider of psychedelic therapeutics for psychiatric disorders. The product pipeline includes CYB003 a deuterated psilocin for the adjunctive treatment of major depressive disorderCYB004 deuterated dimethyltryptamine compound targeting generalized anxiety disorder and CYB005 aphenethylamine derivative treating neuroinflammation.
- Jun 2025Post IPO$50M
- Mar 2024Post IPO$150M
- Mar 2022Post IPO$317.1K
- Feb 2021Post IPO—
#3
Public · Toronto, Ontario · founded 1997$8.6Mraised▾
Developer of psychedelic therapeutics for mental health disorders. The company's psilocybin drug candidates reduce the symptoms of psychological trauma, PTSD, depression, anxiety, stress, and addiction.
- Jun 2025Post IPO$441.1K
- Dec 2024Post IPO$2M
- Aug 2023Post IPO$93.5K
- Apr 2023Post IPO$2.2M
#4
Seed · Toronto, Ontario · founded 2021$14Mraised▾
Developer of medical devices for neurological disease treatment. It offers ultrasound headset that facilitate therapeutic brain stimulation for thw treatment of Alzheimer's and other brain diseases and disorders.
- Jan 2025Seed$14M
#5
Seed · Toronto, Ontario · founded 2015 · 6 employees$1.3Mraised▾
Designer & manufacturer of healthcare gloves. The company claims that its products are designed to intelligently stabilize the wrist joint in Essential Tremor and Parkinson's disease. It allows patients to perform daily activities comfortably. Its gloves are washable and battery-free.
- Sep 2025Grant (prize money)—
- Sep 2025Seed—
- Sep 2025Conventional Debt—
- Jul 2021Seed$884.3K
#6
Series A · Toronto, Ontario · founded 2019 · 9 employees$7Mraised▾
Developer of immunotherapeutics for the treatment of rare diseases. The company has a drug design platform to develop monoclonal antibody (mAb) treatment for protein misfolding diseases. The drug pipeline inlcudes LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases.
- Feb 2025Series A$7M
#7
Public · Toronto, Ontario · founded 2020$500Kraised▾
Developer of therapies for neurodegenerative and neuropsychiatric diseases. It offers myelin repairing compounds which include Lucid-MS a patented neuroprotective compound that prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.
- Nov 2025Post IPO—
- Dec 2024Post IPO$500K
#8
Acquired · Toronto, Ontario · founded 2022 · 18 employees$103Mraised▾
Developer of therapeutics for mental health conditions. The company's product include RE-104 serotonergic psychedelic formulated as a serotonin-2A agonist prodrug for treatment-resistant depression and postpartum depression. also, developing RE-200 series drugs that have selective and specific serotonergic psychedelic candidates.
- Jan 2024Series A$119.8M
#9
Public · Toronto, Ontario · founded 2020 · 2 employees$495.4Kraised▾
Developer of ethnobotanical drug for neurological disorder. It offers Mescaline extracted from cactus which is used to treat anxiety, depression, and substance abuse.
- Mar 2025Seed$359.7K
- Mar 2025Seed$135.7K
#10
Acquired · Toronto, Ontario · founded 1998 · 18 employees$112.8Mraised▾
Transition Therapeutics develops small molecule therapeutics for CNS and metabolic diseases. Its lead candidate has completed phase II trials for two indications: agitation/ aggression associated with Alzheimer's disease and Down's syndrome. In addition, the company has a program for diabetes in phase II trials in partnership with Eli Lilly. For agitation and aggression in Alzheimer's, the candidate, ELND005 or scyllo-inositol, causes a reduction in myo-inositol levels in the brain (similar in effect to lithium and valproic acid), and additionally, ELND005 was associated with a reduction in the levels of beta amyloid and tau proteins in the cerebrospinal fluid.
- Jun 2014Post IPO$17M
- Aug 2013Post IPO$11M
- Nov 2011Post IPO$5M
- Jul 2007Post IPO$23.8M
#11
Public · Toronto, Ontario · founded 2010 · 12 employees$40.1Mraised▾
Bionik Labs provides assistive and rehabilitation hardware and software solutions for healthcare professionals and patients. Offers InMotion Interactive Therapy, that improves upper-extremity motor retraining for patients with neurological conditions and injuries and InMotionConnect which is a software system that assists therapists to monitor & analyze the patient's progress and neurological condition. Also offers InMotionARM, which is a shoulder & elbow evaluation & therapy solution for stroke, spinal cord injury, multiple sclerosis, Parkinson's & other neurological conditions and InMotionARM/HAND which is a solution to treat patients with different deficits such as severe impairment, high level strengthening or coordination.
- May 2017Post IPO—
- Apr 2016Post IPO$27M
- Jul 2015Post IPO$13.1M
#12
Acquired · Toronto, Ontario · founded 2004 · 30 employees$25.1Mraised▾
Cynapsus is developing a fast-acting, sublingual thin film for the potential treatment for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States
- Apr 2015Post IPO$16.8M
- Jul 2014Grant (prize money)$500K
- Apr 2014Series B$20M
- Mar 2013Series A$4.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neurotech in Toronto is moving
A read on the academic research around Neurotech in Toronto — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 524 papers.
- University of Toronto358
- Toronto Western Hospital280
- Toronto Rehabilitation Institute60
- Toronto Public Health14
- Toronto General Hospital4
- Deep brain stimulation6→22
- Stimulation3→11
- Neuromodulation1→6
- Local field potential1→6
- Neuroscience8→13
- Brain stimulation3→15
- Local field potential2→13
- Neuromodulation7→17
- Transcranial magnetic stimulation4→12
- Parkinson's disease16→22
- Stimulation5→13
- Physical medicine and rehabilitation2→8
- Dystonia8→12
- Thalamotomy2→6
- Essential tremor3→6
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.